Edison issues outlook on Tissue Regenix
We recently revisited a number of our key valuation assumptions to reflect the clarity on launch timeframes, associated costs and updated revenue guidance. We maintain our DCF valuation at ?338m or 44.4p per share. According to our model, the current price gives a free option on wound care, the most commercially advanced division, and does not reflect the full pipeline potential, which could ultimately be an acquisition target as a whole or by division.
Click here to view the full report